Publication | Open Access
Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
24
Citations
48
References
2022
Year
www.ClinicalTrials.gov, identifier: NCT02433067.
| Year | Citations | |
|---|---|---|
Page 1
Page 1